Renewed Investor Confidence in Theraclion
17 Décembre 2020 - 6:00PM
Business Wire
Tranche 2 of
investment contract subscribed in full: 3M€ raised Additional PGE
loans for 1.5M€
Regulatory News:
THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE),
an innovative company specialized in echotherapy treatment (using
High Intensity Focused Ultrasound or HIFU) notably for varicose
veins, announces today that it has raised €3.0 million from
investors and obtaining PGE loans from Bpi France and CIC of €1.5
million.
€4.5 million in new funding allows Theraclion to stay ahead,
whilst accelerating commercial rollout
In 2019 Theraclion raised first tranche of €4,8 million from
investors to finance the further development of its SONOVEIN®
technology. This success culminated in the recent CE marking of
SONOVEIN S, the second-generation breakthrough technology for
non-invasive treatment of varicose veins (please see press release
of October 15th this year). Initial treatments with our
technological breakthroughs also confirm excellent clinical results
and were received enthusiastically by specialists. Investors have
subscribed for the full €3 million of the second tranche as
initially planned in 2019. The capital raising also enabled €1.5
million in loans from Bpi France, the public investment bank
responsible for supporting medium-sized and innovative enterprises
and CIC. The funds raised will fund further developments of the
technology and commercialisation and rollout. Theraclion is
committed to stay ahead in innovations and to accelerate the
commercial rollout of the first and only non-invasive treatment for
varicose veins.
About Theraclion
Theraclion has developed an innovative high-tech echotherapy
solution using High Intensity Focused Ultrasound for the treatment
of varicose veins, SONOVEIN®. The treatment solution, which
obtained CE marking in April 2019, is based on the leading-edge
echotherapy treatment expertise developed over years by Theraclion
for non-invasive ablation of breast fibroadenomas and thyroid
nodules using its ECHOPULSE® solution. Further improvements to the
ECHOPULSE technology are the foundation for SONOVEIN to provide the
only non-invasive ablation therapy for varicose veins. This
procedure allows for a treatment without a catheter, chemical
injection, or incision. An operating room is not necessary, and the
treatment can be performed at a doctor’s office, in a clinic, as
well as in a hospital. Venous pathology is widespread worldwide and
generates around 5 million treatment procedures per year, according
to Millennium research Varicose Vein Device Market Study 2015.
Theraclion's technological solutions are based on high-tech
ultrasound medical imaging devices that are precise and easy to use
for practitioners.
Located in Malakoff, near Paris, Theraclion brings together a
team of 25 people, more than half of whom are dedicated to R&D
and clinical trials.
For more information, please visit the Theraclion website:
www.theraclion.com and the patient site:
https://echotherapie.com/echotherapy/
Theraclion is listed on Euronext Growth Paris Eligible for the
PEA-PME scheme Mnemonic: ALTHE - ISIN code: FR0010120402 LEI:
9695007X7HA7A1GCYD29
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201217005740/en/
Theraclion David Caumartin Chief Executive Officer Tél :
+ 33 (0)1 55 48 90 70 david.caumartin@theraclion.com
Anja Kleber VP Marketing, Market Access & Sales Francophonia
anja.kleber@theraclion.com
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Theraclion (EU:ALTHE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024